RecruitingPhase 2NCT07033819

Neoadjuvant Treatment of Ovarian Cancer With Fuzuloparib in Combination With Apatinib

Studying Malignant epithelial tumor of ovary

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Intervention
Neoadjuvant therapy with fuzuloparib in combination with apatinib(drug)
Enrollment
48 target
Eligibility
18-70 years · FEMALE
Timeline
20252028

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT07033819 on ClinicalTrials.gov

Other trials for Malignant epithelial tumor of ovary

Additional recruiting or active studies for the same condition.

See all trials for Malignant epithelial tumor of ovary

← Back to all trials